GLP requirements for the preclinical phase
Studies required as part of the preclinical phase for the marketing authorization process of new medicinal products must be carried out in a GLP-certified laboratory. Exceptions may be applicable for Advanced Therapy Medicinal Products (ATMPs) due to their special characteristics, as described by the EMA and the ICH. A non-application of the GLP regulations must be justified on a case-by-case basis. In addition, GLP regulations are applicable to the safety assessment of chemicals, as for instance required for REACH.
ICH guidelines determine the dataset to be obtained in preclinical studies, as well as their duration. These guidelines have been transferred into mandatory law by the European Commission. They include the ICH safety guidelines S1A, S1B, S1C(R2), S2(R1), and S6(R2), as well as multidisciplinary guidelines, such as ICH M3(R2).